Technical Analysis for RYTM - Rhythm Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade B 29.94 -2.32% -0.71
RYTM closed down 2.32 percent on Friday, March 22, 2019, on 1.49 times normal volume. It was able to bounce off of its 200 day moving average, an important long-term support line. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Flat
See historical RYTM trend table...

Date Alert Name Type % Chg
Mar 22 200 DMA Support Bullish 0.00%
Mar 22 Slingshot Bullish Bullish Swing Setup 0.00%
Mar 22 Multiple of Ten Bearish Other 0.00%
Mar 22 Overbought Stochastic Strength 0.00%
Mar 21 Stochastic Sell Signal Bearish -2.32%
Mar 21 Pocket Pivot Bullish Swing Setup -2.32%
Mar 21 Overbought Stochastic Strength -2.32%
Mar 21 Upper Bollinger Band Touch Strength -2.32%
Mar 20 Slingshot Bullish Bullish Swing Setup -1.06%
Mar 20 Doji - Bearish? Reversal -1.06%

Older signals for RYTM ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies that result in life-threatening metabolic disorders. The Company’s lead peptide product candidate is setmelanotide, a potent, first-in-class melanocortin-4 receptor, or MC4R, agonist for the treatment of rare genetic disorders of obesity. Setmelanotide serves as replacement therapy for the treatment of melanocortin-4, or MC4, pathway deficiencies. MC4 pathway deficiencies result in the disruption of satiety signals and energy homeostasis in the body, which, in turn, leads to intense feelings of hunger and to obesity. The Company also focused on obesity related to six single gene-related, or monogenic, MC4 pathway deficiencies pro-opiomelanocortin, or POMC, leptin receptor, or LepR, Bardet-Biedl syndrome, Alstrom syndrome, POMC heterozygous, and POMC epigenetic disorders.
Biopharmaceutical Medical Specialties Organ Systems Obesity Peptide Hormones Peptides Metabolic Disorders
Is RYTM a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 37.23
52 Week Low 16.8
Average Volume 76,797
200-Day Moving Average 29.5656
50-Day Moving Average 28.7768
20-Day Moving Average 29.211
10-Day Moving Average 29.944
Average True Range 1.3311
ADX 8.77
+DI 19.8908
-DI 17.9906
Chandelier Exit (Long, 3 ATRs ) 27.5617
Chandelier Exit (Short, 3 ATRs ) 29.5133
Upper Bollinger Band 31.4067
Lower Bollinger Band 27.0153
Percent B (%b) 0.67
BandWidth 15.033378
MACD Line 0.4877
MACD Signal Line 0.346
MACD Histogram 0.1417
Fundamentals Value
Market Cap 780.66 Million
Num Shares 26.1 Million
EPS -3.13
Price-to-Earnings (P/E) Ratio -9.57
Price-to-Sales 0.00
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 31.59
Resistance 3 (R3) 31.64 31.14 31.32
Resistance 2 (R2) 31.14 30.72 31.12 31.22
Resistance 1 (R1) 30.54 30.46 30.29 30.49 31.13
Pivot Point 30.04 30.04 29.92 30.02 30.04
Support 1 (S1) 29.44 29.62 29.19 29.39 28.75
Support 2 (S2) 28.94 29.36 28.92 28.66
Support 3 (S3) 28.34 28.94 28.57
Support 4 (S4) 28.29